Secondary prevention for XXXX .

@entity1 @entity1289 @entity583 @entity301 @entity117 @entity951 @entity453 @entity165
BACKGROUND: Secondary prevention of @entity453 is effective in reducing morbidity and mortality, but deficiencies in implementation and prescription bias have been identified. AIM: To assess progress in secondary prevention measures for @entity301 and whether there was a difference between @entity1 subgroups with @entity951 , post @entity583 or revascularization. DESIGN: Retrospective analysis. METHODS: Between 1997 and 2001, data were collected on prophylactic prescribing, demographic and lifestyle information, at baseline and 1 year following attendance at a hospital-based, cardiac-nurse-led out- @entity1 clinic. RESULTS: @entity1 (n = 945) were entered into the database at hospital discharge and 619 (72%) attended at 1 year. @entity117 and statin prescribing increased, though @entity1289 inhibitor use was less. Mean total @entity165 at baseline reduced to 4.92 +/- 0.11 mmol/l (p < 0.001) in 2000, with a further reduction to 4.59 +/- 0.08 mmol/l at the 1-year visit in 2001 (p < 0.001). The proportion of @entity1 with total @entity165 < 5 mmol/l increased to 38% in 2000, reaching 70% in 2001. Smokers at baseline were similar at around 30%, although this had reduced to 10% in 2001 (p < 0.001). No change in weight was seen for @entity1 with BMI >or=30 (p = NS). No significant differences were seen between @entity1 subgroups (p = NS). DISCUSSION: Secondary prevention measures are improving, especially in prophylactic prescribing, lipid management and smoking cessation, although scope for further improvement remains. No difference was seen between the @entity1 subgroups. Lifestyle measures need to be addressed to gain maximum benefit in addressing overall cardiovascular risk.
